Attento — advance in the treatment of arterial hypertension


  • Yu.M. Sirenko State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
  • O.L. Rekovets State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine



arterial hypertension, treatment, olmesartan, amlodipine, fixed combinations, overview


The article deals with the problem of treatment for arterial hypertension. A review of a number of researches aimed at studying the effectiveness of the combination of olmesartan and amlodipine in this pathology is presented.


https: // = arterial + hypertension.

Falaschetti et al. // Lancet. 2014; 383: 1912-19.

Kornelia Kotsev et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 // European countries Journal of Preventive Cardiology. 2015. 1-13. doi: 10.1177/2047487315569401

Omid Fatemi et al. Improvement in All-Cause Morta­-

lity With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension // The Journal of Clinical Hypertension. 2016; Vol. 18, № 1.

Debie L. et al. // The Journal of Clinical Hypertension. 2015; Vol. 17, № 5.

Whelton P.K. et al. High Blood Pressure Clinical Practice Guideline. 2017. http: // 10.1161/HYP.0000000000000065/-/DC1

Thomas J. Wang et al. Is a DASH of Salt All We Need? // J. Am. Coll. Cardiol. 2017; 70(23): 2849-2851.

Dusing R. Adverse events, compliance and changes in the­rapy // Curr. Hypertens Rep. 2001; 3: 488-492.

Ian H. de Boer еt al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association // Diabetes Care. 2017; 40: 1273-1284.

Fleg J.L., Evans G.W., Margolis K.L. et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial: prevalence, incidence, and prognostic significance // Hypertension. 2016; 68: 888-895.

Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. 2008; 358: 1547-1559.

Di Stefano C. et al. Orthostatic hypotension in a cohort of hypertensive patients reffering to a hypertension clinic // Journal of Human Hypertension. 2015; 29: 599-603.

Hazel Mae A. Abraham et al. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases // Drug Saf. 2015 Jan; 38(1): 33-54.

Kiya Y. et al. Clinical and Pharmacotherapeutic Relevance of the Double Chain Domain of the Angiotensin II Type 1 Receptor Blocker Olmesartan // Clin. Exp. Hypertens. 2010; 32(2): 129-136.

Jun Agata et al. Olmesartan Is an Angiotensin II Receptor Blocker with an Inhibitory Effect on Angiotensin-Converting Enzyme // Hypertension Research. 2006. doi: 10.1291/hypres.29.865

Furuhashi M. et al. Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker // Am. J. Hypertens. 2014 May 18.

Furuhashi M. et al. Possible increase in urinary angiotensin­converting enzyme 2 by olmesartan, an angiotensin II receptor blocker, in hypertensive patients // European Heart Journal. 2014; 35 (Abstract Supplement), 66.

Akira Sezai et al. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study) // Ann Thorac Cardiovasc Surg Advance Published Date: April 18, 2016, doi: 10.5761/atcs.oa.16-00054.

Fabia et al. // J. Hypertens. 2007; 25: 1327-36.

Durán A.M., Corcuera J.O. Antihypertensive Efficacy of Fimasartan and Additional Benefits in Patients with Renal Dysfunction // Ann. Clin. Exp. Hypertension. 2017; 5(1): 1046.

Bakris G.L. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure // J. Clin. Hypertens. (Greenwich). 2011; 13(2): 81-8.

White W.B. et al. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension // Hypertension. 2011; 57: 413-420.

Yuhei Shiga et al. Comparison of Effcacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension A Randomized and Prospective Study (CANZONE Study) // Int. Heart J. 2017; 58: 416-421.

Greathouse M., A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations? // CHF. 2002; 8: 313-320.

Volpe M. et al. Is early and fast blood pressure control important in hypertension management? // Int. J. Cardiol. 2017. https: //

Julius S.E. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. 2004; 363: 2022-2031.

Mark A. Munger. Use of Angiotensin Receptor Blockers In Cardiovascular Protection Current Evidence and Future Directions // P&T. 2011; Vol. 36, № 1.

Инструкция для медицинского применения Аттенто № 77 от 09.02.2016.

Mancia G. et al. 2013 ESH/ESC Guidelines for the ma-nagement of arterial hypertension // Eur. Heart J. 2013; 28(34): 2159-2219.

Volpe M. et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study // Clin. Drug. Investig. 2009; 29: 11-25.

Mourad J.J. et al. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study // Clin. Drug. Investig. 2009; 29(6): 419-25.

Fogari R. et al. Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients // Adv. Ther. 2010; 27(1): 48-55.

Ram C.V. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies // Curr. Med. Res. Opin. 2009; 25(1): 177-85.

Cabrera Sole R. Olmesartan plus amlodipine compared to valsartan plus amlodipine reduce more left ventricular hypertrophy and arterial stiffness in mild to moderate hypertensive patients // Journal of Hypertension. 2015; Vol. 33: e-Supplement 1.

Wang, Kang-Ling et al. Central blood pressure and cardiovascular risk // Journal of Hypertension. 2009; Vol. 27,

Is. 8:1713-1714.

Williams B. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. 2006; 113(9): 1213-25.

Luis Ruilope et al. The Fixed-Dose Combination of Olme-sartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomi-zed, Double-Blind Trial in Patients with Hypertension Adv. Ther. 2013; 30: 1086-1099.

Redòn J. et al. Comparative study of the efficacy of olme­sartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes // Journal of Hypertension. 2016; 34: 359-367.

Ogihara T., Saruta T., Rakugi H. et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial // J. Hypertens. 2014; 32(10): 2054-63.

https: //